p300 modulates nuclear morphology in prostate cancer

Jose D. Debes, Thomas J. Sebo, Hannelore V. Heemers, Benjamin R. Kipp, De Anna L. Haugen, Christine M. Lohse, Donald J. Tindall

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Alterations in nuclear structure distinguish cancer cells from noncancer cells. These nuclear alterations can be translated into quantifiable features by digital image analysis in a process known as quantitative nuclear morphometry. Recently, quantitative nuclear morphometry has been shown to predict metastasis and biochemical recurrence of prostate cancer. However, little is known about the cellular mechanisms underlying these nuclear morphometric changes. Alterations of nuclear matrix proteins are frequently involved in changes of nuclear structure. A number of co-activators interact with these nuclear structure-related proteins, suggesting that they might be involved in quantitative nuclear morphometry changes. We have shown previously that the transcriptional co-activator p300 is involved in prostate cancer progression. However, the ability of a transcriptional regulator like p300 to modulate nuclear morphology has not been described previously. In the present study, we show that p300 expression in prostate cancer biopsy tissue from 95 patients correlates with quantifiable nuclear alterations. Moreover, we show that transfection of p300 into prostate cancer cells in culture induces quantifiable nuclear alterations, such as diameter, perimeter, and absorbance among others, as assessed by digital image analysis. These alterations correlate individually with aggressive features in prostate cancer, such as expression of the proliferation marker Ki-67 and extraprostatic extension of the tumor. Finally, we found that transfection of p300 into prostate cancer cells specifically increases mRNA and protein levels of nuclear matrix peptides lamins A and C, suggesting that these proteins mediate the p300-induced effects. These findings reveal a new insight into the transcriptional and structural regulation of prostate cancer.

Original languageEnglish (US)
Pages (from-to)708-712
Number of pages5
JournalCancer Research
Volume65
Issue number3
StatePublished - Feb 1 2005

Fingerprint

Prostatic Neoplasms
Nuclear Matrix-Associated Proteins
Transfection
Lamin Type A
Neoplasms
Proteins
Cell Culture Techniques
Neoplasm Metastasis
Biopsy
Recurrence
Messenger RNA

Cite this

Debes, J. D., Sebo, T. J., Heemers, H. V., Kipp, B. R., Haugen, D. A. L., Lohse, C. M., & Tindall, D. J. (2005). p300 modulates nuclear morphology in prostate cancer. Cancer Research, 65(3), 708-712.

p300 modulates nuclear morphology in prostate cancer. / Debes, Jose D.; Sebo, Thomas J.; Heemers, Hannelore V.; Kipp, Benjamin R.; Haugen, De Anna L.; Lohse, Christine M.; Tindall, Donald J.

In: Cancer Research, Vol. 65, No. 3, 01.02.2005, p. 708-712.

Research output: Contribution to journalArticle

Debes, JD, Sebo, TJ, Heemers, HV, Kipp, BR, Haugen, DAL, Lohse, CM & Tindall, DJ 2005, 'p300 modulates nuclear morphology in prostate cancer', Cancer Research, vol. 65, no. 3, pp. 708-712.
Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DAL, Lohse CM et al. p300 modulates nuclear morphology in prostate cancer. Cancer Research. 2005 Feb 1;65(3):708-712.
Debes, Jose D. ; Sebo, Thomas J. ; Heemers, Hannelore V. ; Kipp, Benjamin R. ; Haugen, De Anna L. ; Lohse, Christine M. ; Tindall, Donald J. / p300 modulates nuclear morphology in prostate cancer. In: Cancer Research. 2005 ; Vol. 65, No. 3. pp. 708-712.
@article{4393cb167a7e43d89f3e5a91ebb6fef6,
title = "p300 modulates nuclear morphology in prostate cancer",
abstract = "Alterations in nuclear structure distinguish cancer cells from noncancer cells. These nuclear alterations can be translated into quantifiable features by digital image analysis in a process known as quantitative nuclear morphometry. Recently, quantitative nuclear morphometry has been shown to predict metastasis and biochemical recurrence of prostate cancer. However, little is known about the cellular mechanisms underlying these nuclear morphometric changes. Alterations of nuclear matrix proteins are frequently involved in changes of nuclear structure. A number of co-activators interact with these nuclear structure-related proteins, suggesting that they might be involved in quantitative nuclear morphometry changes. We have shown previously that the transcriptional co-activator p300 is involved in prostate cancer progression. However, the ability of a transcriptional regulator like p300 to modulate nuclear morphology has not been described previously. In the present study, we show that p300 expression in prostate cancer biopsy tissue from 95 patients correlates with quantifiable nuclear alterations. Moreover, we show that transfection of p300 into prostate cancer cells in culture induces quantifiable nuclear alterations, such as diameter, perimeter, and absorbance among others, as assessed by digital image analysis. These alterations correlate individually with aggressive features in prostate cancer, such as expression of the proliferation marker Ki-67 and extraprostatic extension of the tumor. Finally, we found that transfection of p300 into prostate cancer cells specifically increases mRNA and protein levels of nuclear matrix peptides lamins A and C, suggesting that these proteins mediate the p300-induced effects. These findings reveal a new insight into the transcriptional and structural regulation of prostate cancer.",
author = "Debes, {Jose D.} and Sebo, {Thomas J.} and Heemers, {Hannelore V.} and Kipp, {Benjamin R.} and Haugen, {De Anna L.} and Lohse, {Christine M.} and Tindall, {Donald J.}",
year = "2005",
month = "2",
day = "1",
language = "English (US)",
volume = "65",
pages = "708--712",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - p300 modulates nuclear morphology in prostate cancer

AU - Debes, Jose D.

AU - Sebo, Thomas J.

AU - Heemers, Hannelore V.

AU - Kipp, Benjamin R.

AU - Haugen, De Anna L.

AU - Lohse, Christine M.

AU - Tindall, Donald J.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Alterations in nuclear structure distinguish cancer cells from noncancer cells. These nuclear alterations can be translated into quantifiable features by digital image analysis in a process known as quantitative nuclear morphometry. Recently, quantitative nuclear morphometry has been shown to predict metastasis and biochemical recurrence of prostate cancer. However, little is known about the cellular mechanisms underlying these nuclear morphometric changes. Alterations of nuclear matrix proteins are frequently involved in changes of nuclear structure. A number of co-activators interact with these nuclear structure-related proteins, suggesting that they might be involved in quantitative nuclear morphometry changes. We have shown previously that the transcriptional co-activator p300 is involved in prostate cancer progression. However, the ability of a transcriptional regulator like p300 to modulate nuclear morphology has not been described previously. In the present study, we show that p300 expression in prostate cancer biopsy tissue from 95 patients correlates with quantifiable nuclear alterations. Moreover, we show that transfection of p300 into prostate cancer cells in culture induces quantifiable nuclear alterations, such as diameter, perimeter, and absorbance among others, as assessed by digital image analysis. These alterations correlate individually with aggressive features in prostate cancer, such as expression of the proliferation marker Ki-67 and extraprostatic extension of the tumor. Finally, we found that transfection of p300 into prostate cancer cells specifically increases mRNA and protein levels of nuclear matrix peptides lamins A and C, suggesting that these proteins mediate the p300-induced effects. These findings reveal a new insight into the transcriptional and structural regulation of prostate cancer.

AB - Alterations in nuclear structure distinguish cancer cells from noncancer cells. These nuclear alterations can be translated into quantifiable features by digital image analysis in a process known as quantitative nuclear morphometry. Recently, quantitative nuclear morphometry has been shown to predict metastasis and biochemical recurrence of prostate cancer. However, little is known about the cellular mechanisms underlying these nuclear morphometric changes. Alterations of nuclear matrix proteins are frequently involved in changes of nuclear structure. A number of co-activators interact with these nuclear structure-related proteins, suggesting that they might be involved in quantitative nuclear morphometry changes. We have shown previously that the transcriptional co-activator p300 is involved in prostate cancer progression. However, the ability of a transcriptional regulator like p300 to modulate nuclear morphology has not been described previously. In the present study, we show that p300 expression in prostate cancer biopsy tissue from 95 patients correlates with quantifiable nuclear alterations. Moreover, we show that transfection of p300 into prostate cancer cells in culture induces quantifiable nuclear alterations, such as diameter, perimeter, and absorbance among others, as assessed by digital image analysis. These alterations correlate individually with aggressive features in prostate cancer, such as expression of the proliferation marker Ki-67 and extraprostatic extension of the tumor. Finally, we found that transfection of p300 into prostate cancer cells specifically increases mRNA and protein levels of nuclear matrix peptides lamins A and C, suggesting that these proteins mediate the p300-induced effects. These findings reveal a new insight into the transcriptional and structural regulation of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=13444279879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444279879&partnerID=8YFLogxK

M3 - Article

C2 - 15705864

AN - SCOPUS:13444279879

VL - 65

SP - 708

EP - 712

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -